Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009)

Goffredo, V.; Paradiso, Angelo; Ranieri, Girolamo; Gadaleta, Cosmo Damiano

doi:10.1016/j.critrevonc.2011.01.012

Cited by 35 publications

(33 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…111 In is a common γ-emitting radionuclide used in the clinic for SPECT imaging [26]. 90 Y as a beta emitting radionuclide has been clinically used for radiotherapeutic treatment of tumors [27]. 111 In and 90 Y have similar half-lives (2.80 and 2.67 days, respectively) that correspond to the potential biological half-life of HPMA copolymer construct.…”

Section: Resultsmentioning

confidence: 99%

Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors

Buckway

Frazier

Gormley

et al. 2014

Nuclear Medicine and Biology

View full text Add to dashboard Cite

Introduction-The treatment of prostate cancer using a radiotherapeutic 90 Y labeled N-(2-hydroxypropyl)methacrylamide (HPMA)copolymer can be enhanced with localized tumor hyperthermia. An 111 In labeled HPMA copolymer system for single photon emission computerized tomography (SPECT) was developed to observe the biodistribution changes associated with hyperthermia. Efficacy studies were conducted in prostate tumor bearing mice using the 90 Y HPMA copolymer with hyperthermia.

show abstract

Section: Resultsmentioning

confidence: 99%

Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors

Buckway

Frazier

Gormley

et al. 2014

Nuclear Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…High-energy radiation from 90 Y-loaded microspheres, locally injected via catheterization, is used to destroy active tumor cells [1][2][3][4]. As an almost pure electron emitter, 90 Y has a number of attractive characteristics, for example its long half-life of 64.2 h and a high mean (max) particle energy of 0.94 MeV (2.28 MeV) [5].…”

mentioning

confidence: 99%

Study-Parameter Impact in Quantitative 90-Yttrium PET Imaging for Radioembolization Treatment Monitoring and Dosimetry

Goedicke

Berker

Verburg

et al. 2013

IEEE Trans. Med. Imaging

View full text Add to dashboard Cite

A small positron-generating branch in 90-Yttrium ((90)Y) decay enables post-therapy dose assessment in liver cancer radioembolization treatment. The aim of this study was to validate clinical (90)Y positron emission tomography (PET) quantification, focusing on scanner linearity as well as acquisition and reconstruction parameter impact on scanner calibration. Data from three dedicated phantom studies (activity range: 55.2 MBq-2.1 GBq) carried out on a Philips Gemini TF 16 PET/CT scanner were analyzed after reconstruction with up to 361 parameter configurations. For activities above 200 MBq, scanner linearity could be confirmed with relative error margins 4%. An acquisition-time-normalized calibration factor of 1.04 MBq·s/CNTS was determined for the employed scanner. Stable activity convergence was found in hot phantom regions with relative differences in summed image intensities between -3.6% and +2.4%. Absolute differences in background noise artifacts between - 79.9% and + 350% were observed. Quantitative accuracy was dominated by subset size selection in the reconstruction. Using adequate segmentation and optimized acquisition parameters, the average activity recovery error induced by the axial scanner sensitivity profile was reduced to +2.4%±3.4% (mean ± standard deviation). We conclude that post-therapy dose assessment in (90)Y PET can be improved using adapted parameter setups.

show abstract

“…Lipiodol has been labelled with iodine-131 (Liebster and Kocandrle, 1964;Raoul et al, 1986), rhenium-188 (Lepareur et al, 2008), yttrium-90 (Wang et al, 1996b;Yu et al, 2003), and radiolanthanides (Das et al, 2009;Subramanian et al, 2010). Yttrium-90 (pure beta-emitter, E β max ¼2.27 MeV, t 1/2 ¼64 h, max tissue penetration¼ 12 mm) has ideal properties for targeted radiotherapy, and has found wide use in peptide receptor radionuclide therapy (Goffredo et al, 2011), radioimmunotherapy (Sharkey et al, 2010) and radioembolisation (Salem and Hunter, 2006). It has been suggested as a suitable isotope to label Lipiodol as it should lead to a significantly reduced whole-body dose compared to 131 I-Lipiodol, since more than 90% of this dose is due to the emitted gamma rays (respectively Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/apradiso 0.02 rad/mCi compared to 1.9 rad/mCi, based on estimated dosimetry) (Madsen et al, 1988).…”

Section: Introductionmentioning

confidence: 98%

Mixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinoma

López

Noiret

Garin

et al. 2014

Applied Radiation and Isotopes

View full text Add to dashboard Cite

Yttrium-90 is a radioelement which has found wide use in targeted radionuclide therapy because of its attractive physical and chemical properties. Radioembolisation of hepatocellular carcinoma with radiolabelled Lipiodol is a method of choice. We have synthesised a series of alkyldithiocarbamate yttrium complexes, easily extracted into Lipiodol due to their high lipophilicity. Among the prepared series, a new radioconjugate, which is stable over an extended period of time, has been prepared, and could represent a potential treatment procedure for hepatocellular carcinoma.

show abstract

Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009)

Cited by 35 publications

References 122 publications

Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors

Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors

Study-Parameter Impact in Quantitative 90-Yttrium PET Imaging for Radioembolization Treatment Monitoring and Dosimetry

Mixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinoma

Contact Info

Product

Resources

About